{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:06:38Z","timestamp":1783008398318,"version":"3.54.5"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,24]]},"DOI":"10.7759\/cureus.81086","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T20:35:14Z","timestamp":1742848514000},"source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic Uses and Efficacy of Low-Dose Naltrexone: A Scoping Review"],"prefix":"10.7759","author":[{"given":"Kayla K","family":"Leiber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Alternatives to Opioids for Managing Pain","author":"Dey S","year":"2025","unstructured":"Dey S, Sanders AE, Martinez S, Kopitnik NL, Vrooman BM. Alternatives to Opioids for Managing Pain. StatPearls [Internet], StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7215a1","article-title":"Chronic pain among adults - United States, 2019-2021","volume":"72","author":"Rikard SM","year":"2023","unstructured":"Rikard SM, Strahan AE, Schmit KM, Guy GP Jr. Chronic pain among adults - United States, 2019-2021. MMWR Morb Mortal Wkly Rep. 2023, 72:379-85. 10.15585\/mmwr.mm7215a1","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2517-2","article-title":"The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain","volume":"33","author":"Younger J","year":"2014","unstructured":"Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014, 33:451-9. 10.1007\/s10067-014-2517-2","journal-title":"Clin Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-020-00898-0","article-title":"Low-dose naltrexone for chronic pain: update and systemic review","volume":"24","author":"Kim PS","year":"2020","unstructured":"Kim PS, Fishman MA. Low-dose naltrexone for chronic pain: update and systemic review. Curr Pain Headache Rep. 2020, 24:64. 10.1007\/s11916-020-00898-0","journal-title":"Curr Pain Headache Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMAScR): checklist and explanation","volume":"169","author":"Tricco AC","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, et al.. PRISMA extension for scoping reviews (PRISMAScR): checklist and explanation. Ann Intern Med. 2018, 169:467-73. 10.7326\/M18-0850","journal-title":"Ann Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.2446","article-title":"Treatment of Hailey-Hailey disease with low-dose naltrexone","volume":"153","author":"Albers LN","year":"2017","unstructured":"Albers LN, Arbiser JL, Feldman RJ. Treatment of Hailey-Hailey disease with low-dose naltrexone. JAMA Dermatol. 2017, 153:1018-20. 10.1001\/jamadermatol.2017.2446","journal-title":"JAMA Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2023.03.013","article-title":"Pilot study of low-dose naltrexone for the treatment of chronic pain due to arthritis: a randomized, double-blind, placebo-controlled, crossover clinical trial","volume":"45","author":"Beaudette-Zlatanova B","year":"2023","unstructured":"Beaudette-Zlatanova B, Lew RA, Otis JD, et al.. Pilot study of low-dose naltrexone for the treatment of chronic pain due to arthritis: a randomized, double-blind, placebo-controlled, crossover clinical trial. Clin Ther. 2023, 45:468-77. 10.1016\/j.clinthera.2023.03.013","journal-title":"Clin Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.3943","article-title":"Low-dose naltrexone: an alternative treatment for erythrodermic psoriasis","volume":"11","author":"Beltran Monasterio EP","year":"2019","unstructured":"Beltran Monasterio EP. Low-dose naltrexone: an alternative treatment for erythrodermic psoriasis. Cureus. 2019, 11:e3943. 10.7759\/cureus.3943","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000001080","article-title":"Low-dose naltrexone for treatment of pain in patients with fibromyalgia: a randomized, double-blind, placebo-controlled, crossover study","volume":"8","author":"Bested K","year":"2023","unstructured":"Bested K, Jensen LM, Andresen T, et al.. Low-dose naltrexone for treatment of pain in patients with fibromyalgia: a randomized, double-blind, placebo-controlled, crossover study. Pain Rep. 2023, 8:e1080. 10.1097\/PR9.0000000000001080","journal-title":"Pain Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-232502","article-title":"Low-dose naltrexone as a treatment for chronic fatigue syndrome","volume":"13","author":"Bolton MJ","year":"2020","unstructured":"Bolton MJ, Chapman BP, Van Marwijk H. Low-dose naltrexone as a treatment for chronic fatigue syndrome. BMJ Case Rep. 2020, 13:e232502. 10.1136\/bcr-2019-232502","journal-title":"BMJ Case Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110966","article-title":"Low-dose naltrexone use for the management of post-acute sequelae of COVID-19","volume":"124","author":"Bonilla H","year":"2023","unstructured":"Bonilla H, Tian L, Marconi VC, et al.. Low-dose naltrexone use for the management of post-acute sequelae of COVID-19. Int Immunopharmacol. 2023, 124:110966. 10.1016\/j.intimp.2023.110966","journal-title":"Int Immunopharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnaa001","article-title":"Low-dose naltrexone for the treatment of fibromyalgia: investigation of dose-response relationships","volume":"21","author":"Bruun-Plesner K","year":"2020","unstructured":"Bruun-Plesner K, Blichfeldt-Eckhardt MR, Vaegter HB, Lauridsen JT, Amris K, Toft P. Low-dose naltrexone for the treatment of fibromyalgia: investigation of dose-response relationships. Pain Med. 2020, 21:2253-61. 10.1093\/pm\/pnaa001","journal-title":"Pain Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.336_9","article-title":"Low-dose naltrexone (LDN) treatment for Crohn\u2019s disease (CD): a tertiary care center experience","volume":"106","author":"Choksi Y","year":"2011","unstructured":"Choksi Y, Beaulieu D, Horst S, Wagnon J, Duley C, Schwartz D. Low-dose naltrexone (LDN) treatment for Crohn\u2019s disease (CD): a tertiary care center experience. Am J Gastroenterol. 2011, 106:S461. 10.1038\/ajg.2011.336_9","journal-title":"Am J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-013-9451-y","article-title":"Treatment of complex regional pain syndrome (CRPS) using low dose naltrexone (LDN)","volume":"8","author":"Chopra P","year":"2013","unstructured":"Chopra P, Cooper MS. Treatment of complex regional pain syndrome (CRPS) using low dose naltrexone (LDN). J Neuroimmune Pharmacol. 2013, 8:470-6. 10.1007\/s11481-013-9451-y","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref15","article-title":"Low dose naltrexone in conjunction with the Wahls protocol to reduce the frequency of chronic migraines in a patient with multiple sclerosis: a case study","volume":"20","author":"Codino H","year":"2021","unstructured":"Codino H, Hardin A. Low dose naltrexone in conjunction with the Wahls protocol to reduce the frequency of chronic migraines in a patient with multiple sclerosis: a case study. Integr Med (Encinitas). 2021, 20:30-4.","journal-title":"Integr Med (Encinitas)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.33321","article-title":"Combination of naltrexone and isotretinoin for the treatment of Darier disease","volume":"15","author":"Costa T","year":"2023","unstructured":"Costa T, Rebelo C, Marques Pinto G, Duarte B. Combination of naltrexone and isotretinoin for the treatment of Darier disease. Cureus. 2023, 15:e33321. 10.7759\/cureus.33321","journal-title":"Cureus"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22006","article-title":"Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis","volume":"68","author":"Cree BA","year":"2010","unstructured":"Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010, 68:145-50. 10.1002\/ana.22006","journal-title":"Ann Neurol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S1873-9946(12)60406-1","article-title":"Immunological changes in IBD patients responding to low-dose naltrexone treatment","volume":"6","author":"De Haar C","year":"2012","unstructured":"De Haar C, Van Der Ent C, Peppelenbosch MP, Van Der Woude CJ. Immunological changes in IBD patients responding to low-dose naltrexone treatment. J Crohns Colitis. 2012, 6:S164. 10.1016\/S1873-9946(12)60406-1","journal-title":"J Crohns Colitis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2020.12.003","article-title":"Low-dose naltrexone is effective and well-tolerated for modulating symptoms in patients with neuropathic corneal pain","volume":"20","author":"Dieckmann G","year":"2021","unstructured":"Dieckmann G, Ozmen MC, Cox SM, Engert RC, Hamrah P. Low-dose naltrexone is effective and well-tolerated for modulating symptoms in patients with neuropathic corneal pain. Ocul Surf. 2021, 20:33-8. 10.1016\/j.jtos.2020.12.003","journal-title":"Ocul Surf"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11041087","article-title":"Efficacy of low-dose naltrexone and predictors of treatment success or discontinuation in fibromyalgia and other chronic pain conditions: a fourteen-year, enterprise-wide retrospective analysis","volume":"11","author":"Driver CN","year":"2023","unstructured":"Driver CN, D'Souza RS. Efficacy of low-dose naltrexone and predictors of treatment success or discontinuation in fibromyalgia and other chronic pain conditions: a fourteen-year, enterprise-wide retrospective analysis. Biomedicines. 2023, 11:1087. 10.3390\/biomedicines11041087","journal-title":"Biomedicines"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00278-3","article-title":"Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial","volume":"6","author":"Due Bruun K","year":"2024","unstructured":"Due Bruun K, Christensen R, Amris K, et al.. Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. 2024, 6:e31-9. 10.1016\/S2665-9913(23)00278-3","journal-title":"Lancet Rheumatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/804296","article-title":"Low-dose naltrexone for pruritus in systemic sclerosis","volume":"2011","author":"Frech T","year":"2011","unstructured":"Frech T, Novak K, Revelo MP, et al.. Low-dose naltrexone for pruritus in systemic sclerosis. Int J Rheumatol. 2011, 2011:804296. 10.1155\/2011\/804296","journal-title":"Int J Rheumatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.34169","article-title":"Oral low-dose naltrexone in the treatment of frontal fibrosing alopecia and lichen planopilaris: an uncontrolled open-label prospective study","volume":"15","author":"Hamel RK","year":"2023","unstructured":"Hamel RK, Chen L, O'Connell C, Mann C. Oral low-dose naltrexone in the treatment of frontal fibrosing alopecia and lichen planopilaris: an uncontrolled open-label prospective study. Cureus. 2023, 15:e34169. 10.7759\/cureus.34169","journal-title":"Cureus"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.2445","article-title":"Low-dose naltrexone treatment of familial benign pemphigus (Hailey-Hailey disease)","volume":"153","author":"Ibrahim O","year":"2017","unstructured":"Ibrahim O, Hogan SR, Vij A, Fernandez AP. Low-dose naltrexone treatment of familial benign pemphigus (Hailey-Hailey disease). JAMA Dermatol. 2017, 153:1015-7. 10.1001\/jamadermatol.2017.2445","journal-title":"JAMA Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2016.1232064","article-title":"Theme 9 therapeutic strategies","volume":"17","year":"2016","unstructured":"Theme 9 therapeutic strategies. Amyotroph Lateral Scler Frontotemporal Degener. 2016, 17.236-63. 10.1080\/21678421.2016.1232064","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2024.100733","article-title":"Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19","volume":"36","author":"Isman A","year":"2024","unstructured":"Isman A, Nyquist A, Strecker B, Harinath G, Lee V, Zhang X, Zalzala S. Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19. Brain Behav Immun Health. 2024, 36:100733. 10.1016\/j.bbih.2024.100733","journal-title":"Brain Behav Immun Health"},{"key":"ref27","article-title":"The efficacy of low-dose naltrexone as a therapeutic alternative for fibromyalgia, chronic pain syndrome, and multiple sclerosis: a retrospective chart review","volume":"13","author":"Jahangiri AA","year":"2021","unstructured":"Jahangiri AA, Lesko A, Nguyen K, Baraban E, Roos H. The efficacy of low-dose naltrexone as a therapeutic alternative for fibromyalgia, chronic pain syndrome, and multiple sclerosis: a retrospective chart review. PM R. 2021, 13:S1-S229.","journal-title":"PM R"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000438656.15392.e8","article-title":"Low-dose naltrexone therapy improves active ulcerative colitis","volume":"19","author":"Kais S","year":"2013","unstructured":"Kais S. Low-dose naltrexone therapy improves active ulcerative colitis. Inflamm Bowel Dis. 2013, 19:S29. 10.1097\/01.MIB.0000438656.15392.e8","journal-title":"Inflamm Bowel Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.29271\/jcpsp.2020.06.579","article-title":"Efficacy of low dose naltrexone in psoriasis","volume":"30","author":"Khan S","year":"2020","unstructured":"Khan S, Ghafoor R, Kaleem S. Efficacy of low dose naltrexone in psoriasis. J Coll Physicians Surg Pak. 2020, 30:579-83. 10.29271\/jcpsp.2020.06.579","journal-title":"J Coll Physicians Surg Pak"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1427-5","article-title":"Low dose naltrexone for induction of remission in inflammatory bowel disease patients","volume":"16","author":"Lie MR","year":"2018","unstructured":"Lie MR, van der Giessen J, Fuhler GM, de Lima A, Peppelenbosch MP, van der Ent C, van der Woude CJ. Low dose naltrexone for induction of remission in inflammatory bowel disease patients. J Transl Med. 2018, 16:55. 10.1186\/s12967-018-1427-5","journal-title":"J Transl Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X20984121","article-title":"Improvement in Hailey-Hailey disease with a combination of low-dose naltrexone and oral magnesium chloride: a case report","volume":"8","author":"Lim D","year":"2020","unstructured":"Lim D, Belisle A, Davar S. Improvement in Hailey-Hailey disease with a combination of low-dose naltrexone and oral magnesium chloride: a case report. SAGE Open Med Case Rep. 2020, 8:2050313X20984121. 10.1177\/2050313X20984121","journal-title":"SAGE Open Med Case Rep"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1177\/2055217316672242","article-title":"Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis","volume":"2","author":"Ludwig MD","year":"2016","unstructured":"Ludwig MD, Turel AP, Zagon IS, McLaughlin PJ. Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis. Mult Scler J Exp Transl Clin. 2016, 2:2055217316672242. 10.1177\/2055217316672242","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"ref33","doi-asserted-by":"crossref","DOI":"10.5070\/D3256044451","article-title":"Low-dose naltrexone: a unique treatment for amyopathic dermatomyositis","volume":"25","author":"Manudhane AP","year":"2019","unstructured":"Manudhane AP, Schrom KP, Ezaldein HH, Armile JA. Low-dose naltrexone: a unique treatment for amyopathic dermatomyositis. Dermatol Online J. 2019, 25:13030\/qt89b75552.","journal-title":"Dermatol Online J"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S451183","article-title":"Effective doses of low-dose naltrexone for chronic pain - an observational study","volume":"17","author":"Marcus NJ","year":"2024","unstructured":"Marcus NJ, Robbins L, Araki A, Gracely EJ, Theoharides TC. Effective doses of low-dose naltrexone for chronic pain - an observational study. J Pain Res. 2024, 17:1273-84. 10.2147\/JPR.S451183","journal-title":"J Pain Res"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S389957","article-title":"Low-dose naltrexone (LDN) for chronic pain at a single institution: a case series","volume":"16","author":"McKenzie-Brown AM","year":"2023","unstructured":"McKenzie-Brown AM, Boorman DW, Ibanez KR, Agwu E, Singh V. Low-dose naltrexone (LDN) for chronic pain at a single institution: a case series. J Pain Res. 2023, 16:1993-8. 10.2147\/JPR.S389957","journal-title":"J Pain Res"},{"key":"ref36","doi-asserted-by":"crossref","DOI":"10.14309\/00000434-201510001-01005","article-title":"An open label trial of low-dose naltrexone (LDN) for symptomatic mesenteric panniculitis","volume":"110","author":"Melitas C","year":"2015","unstructured":"Melitas C, Roginsky G, Alexoff A, Ehrenpreis ED. An open label trial of low-dose naltrexone (LDN) for symptomatic mesenteric panniculitis. Am J Gastroenterol. 2015, 110:S434-5.","journal-title":"Am J Gastroenterol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.2174\/1573397113666170321120329","article-title":"Low dose naltrexone in the treatment of fibromyalgia","volume":"14","author":"Metyas S","year":"2018","unstructured":"Metyas S, Chen CL, Yeter K, Solyman J, Arkfeld DG. Low dose naltrexone in the treatment of fibromyalgia. Curr Rheumatol Rev. 2018, 14:177-80. 10.2174\/1573397113666170321120329","journal-title":"Curr Rheumatol Rev"},{"key":"ref38","article-title":"Recalcitrant Hailey-Hailey disease successfully treated with low-dose naltrexone","volume":"13","author":"Michael M","year":"2020","unstructured":"Michael M, Benjamin M W, Shannon C T. Recalcitrant Hailey-Hailey disease successfully treated with low-dose naltrexone. J Clin Aesthet Dermatol. 2020, 13:19-21.","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2016.08.029","article-title":"Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants","volume":"208","author":"Mischoulon D","year":"2017","unstructured":"Mischoulon D, Hylek L, Yeung AS, et al.. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. J Affect Disord. 2017, 208:6-14. 10.1016\/j.jad.2016.08.029","journal-title":"J Affect Disord"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.2924","article-title":"Low dose naltrexone and lung cancer: a case report and discussion","volume":"10","author":"Miskoff JA","year":"2018","unstructured":"Miskoff JA, Chaudhri M. Low dose naltrexone and lung cancer: a case report and discussion. Cureus. 2018, 10:e2924. 10.7759\/cureus.2924","journal-title":"Cureus"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1080\/15360288.2024.2302550","article-title":"Efficacy and safety of low dose naltrexone for chronic pain","volume":"38","author":"N Irwin M","year":"2024","unstructured":"N Irwin M, A Cooke D, Berland D, D Marshall V, A Smith M. Efficacy and safety of low dose naltrexone for chronic pain. J Pain Palliat Care Pharmacother. 2024, 38:13-9. 10.1080\/15360288.2024.2302550","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(15)32952-8","article-title":"Low dose naltrexone in the treatment of Crohn\u2019s disease: a case series","volume":"148","author":"Nathoo S","year":"2015","unstructured":"Nathoo S, Glover SC. Low dose naltrexone in the treatment of Crohn\u2019s disease: a case series. Gastroenterol. 2015, 148:S870. 10.1016\/S0016-5085(15)32952-8","journal-title":"Gastroenterol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2022.100485","article-title":"Safety and efficacy of low dose naltrexone in a long COVID cohort; an interventional pre-post study","volume":"24","author":"O'Kelly B","year":"2022","unstructured":"O'Kelly B, Vidal L, McHugh T, Woo J, Avramovic G, Lambert JS. Safety and efficacy of low dose naltrexone in a long COVID cohort; an interventional pre-post study. Brain Behav Immun Health. 2022, 24:100485. 10.1016\/j.bbih.2022.100485","journal-title":"Brain Behav Immun Health"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.546","article-title":"Variable response of Hailey-Hailey disease to naltrexone: a case series","volume":"81","author":"Patel PD","year":"2019","unstructured":"Patel PD, Barry SN, Clark S, Hoffman M, Hernandez C. Variable response of Hailey-Hailey disease to naltrexone: a case series. J Am Acad Dermatol. 2019, 81:AB146. 10.1016\/j.jaad.2019.06.546","journal-title":"J Am Acad Dermatol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjane.2022.08.003","article-title":"Association of low-dose naltrexone and transcranial direct current stimulation in fibromyalgia: a randomized, double-blinded, parallel clinical trial","volume":"73","author":"Paula TM","year":"2023","unstructured":"Paula TM, Castro MS, Medeiros LF, et al.. Association of low-dose naltrexone and transcranial direct current stimulation in fibromyalgia: a randomized, double-blinded, parallel clinical trial. Braz J Anesthesiol. 2023, 73:409-17. 10.1016\/j.bjane.2022.08.003","journal-title":"Braz J Anesthesiol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06738-0","article-title":"Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial","volume":"30","author":"Peters KB","year":"2022","unstructured":"Peters KB, Affronti ML, Woodring S, et al.. Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial. Support Care Cancer. 2022, 30:3463-71. 10.1007\/s00520-021-06738-0","journal-title":"Support Care Cancer"},{"key":"ref47","article-title":"Low dose naltrexone: side effects and efficacy in gastrointestinal disorders","volume":"14","author":"Ploesser J","year":"2010","unstructured":"Ploesser J, Weinstock LB, Thomas E. Low dose naltrexone: side effects and efficacy in gastrointestinal disorders. Int J Pharm Compd. 2010, 14:171-3.","journal-title":"Int J Pharm Compd"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1080\/21641846.2019.1692770","article-title":"Low-dose naltrexone in the treatment of myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS)","volume":"7","author":"Polo O","year":"2019","unstructured":"Polo O, Pesonen P, Tuominen E. Low-dose naltrexone in the treatment of myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS). Fatigue Biomed Health Behav. 2019, 7:207-17. 10.1080\/21641846.2019.1692770","journal-title":"Fatigue Biomed Health Behav"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy008","article-title":"The effect of low-dose naltrexone on medication in inflammatory bowel disease: a quasi experimental before-and-after prescription database study","volume":"12","author":"Raknes G","year":"2018","unstructured":"Raknes G, Simonsen P, Sm\u00e5brekke L. The effect of low-dose naltrexone on medication in inflammatory bowel disease: a quasi experimental before-and-after prescription database study. J Crohns Colitis. 2018, 12:677-86. 10.1093\/ecco-jcc\/jjy008","journal-title":"J Crohns Colitis"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187423","article-title":"Low dose naltrexone in multiple sclerosis: effects on medication use. A quasi-experimental study","volume":"12","author":"Raknes G","year":"2017","unstructured":"Raknes G, Sm\u00e5brekke L. Low dose naltrexone in multiple sclerosis: effects on medication use. A quasi-experimental study. PLoS One. 2017, 12:e0187423. 10.1371\/journal.pone.0187423","journal-title":"PLoS One"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212460","article-title":"Low dose naltrexone: effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study","volume":"14","author":"Raknes G","year":"2019","unstructured":"Raknes G, Sm\u00e5brekke L. Low dose naltrexone: effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study. PLoS One. 2019, 14:e0212460. 10.1371\/journal.pone.0212460","journal-title":"PLoS One"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.brs.2018.12.216","article-title":"Low dose naltrexone: a viable alternative for long term chronic pain?","volume":"12","author":"Rivera V","year":"2019","unstructured":"Rivera V, DeCicco J, Espiritu S. Low dose naltrexone: a viable alternative for long term chronic pain? . Brain Stimul. 2019, 12:e118-20. 10.1016\/j.brs.2018.12.216","journal-title":"Brain Stimul"},{"key":"ref53","article-title":"Low-dose naltrexone and pain relief in gadolinium deposition disease: a case series","volume":"6","author":"Ruhoy I","year":"2022","unstructured":"Ruhoy I, Koran LM. Low-dose naltrexone and pain relief in gadolinium deposition disease: a case series. Interv Pain Manag Rep. 2022, 6:99-102.","journal-title":"Interv Pain Manag Rep"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.oooo.2022.04.048","article-title":"Low-dose naltrexone for treatment of burning mouth syndrome","volume":"135","author":"Sangalli L","year":"2023","unstructured":"Sangalli L, Miller CS. Low-dose naltrexone for treatment of burning mouth syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol. 2023, 135:e83-8. 10.1016\/j.oooo.2022.04.048","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510366857","article-title":"The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial","volume":"16","author":"Sharafaddinzadeh N","year":"2010","unstructured":"Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Mult Scler. 2010, 16:964-9. 10.1177\/1352458510366857","journal-title":"Mult Scler"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.22677","article-title":"Depression in fibromyalgia patients may require low-dose naltrexone to respond: a case report","volume":"14","author":"Siembida J","year":"2022","unstructured":"Siembida J, Johnson B. Depression in fibromyalgia patients may require low-dose naltrexone to respond: a case report. Cureus. 2022, 14:e22677. 10.7759\/cureus.22677","journal-title":"Cureus"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3182702f2b","article-title":"Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study","volume":"47","author":"Smith JP","year":"2013","unstructured":"Smith JP, Field D, Bingaman SI, Evans R, Mauger DT. Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study. J Clin Gastroenterol. 2013, 47:339-45. 10.1097\/MCG.0b013e3182702f2b","journal-title":"J Clin Gastroenterol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.24875\/HGMX.21000039","article-title":"Naltrexone, a therapeutic alternative in Darier disease","volume":"84","author":"Smith-Pellegrin DL","year":"2021","unstructured":"Smith-Pellegrin DL, Rivera-Vega MR, Cazar\u00edn-Barrientos JR, Melgarejo-G\u00f3mez A, Messina-Baas OM, Cuevas-Covarrubias S. Naltrexone, a therapeutic alternative in Darier disease. Rev Med Hosp Gen Mex. 2021, 84:177-80. 10.24875\/HGMX.21000039","journal-title":"Rev Med Hosp Gen Mex"},{"key":"ref59","article-title":"Management of pediatric complex regional pain syndrome with low-dose naltrexone","volume":"5","author":"Soin A","year":"2021","unstructured":"Soin A. Management of pediatric complex regional pain syndrome with low-dose naltrexone. Pain Med Case Rep. 2021, 5:109-13.","journal-title":"Pain Med Case Rep"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-020-05705-0","article-title":"Vulvar Hailey-Hailey disease treated with low-dose naltrexone: case report and literature review","volume":"302","author":"Sousa Gomes M","year":"2020","unstructured":"Sousa Gomes M, Ara\u00fajo Pereira J, Trocado V, Prata JP, Teixeira V, Pinheiro P. Vulvar Hailey-Hailey disease treated with low-dose naltrexone: case report and literature review. Arch Gynecol Obstet. 2020, 302:1081-6. 10.1007\/s00404-020-05705-0","journal-title":"Arch Gynecol Obstet"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.13202","article-title":"Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: a randomized, double-blind, active-control, crossover clinical trial","volume":"13","author":"Srinivasan A","year":"2021","unstructured":"Srinivasan A, Dutta P, Bansal D, Chakrabarti A, Bhansali AK, Hota D. Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: a randomized, double-blind, active-control, crossover clinical trial. J Diabetes. 2021, 13:770-8. 10.1111\/1753-0407.13202","journal-title":"J Diabetes"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.43426","article-title":"Low-dose naltrexone use in postural orthostatic tachycardia syndrome: a case series","volume":"15","author":"Stallkamp Tidd SJ","year":"2023","unstructured":"Stallkamp Tidd SJ, Cantrell C, Greene BD, Wilson R. Low-dose naltrexone use in postural orthostatic tachycardia syndrome: a case series. Cureus. 2023, 15:e43426. 10.7759\/cureus.43426","journal-title":"Cureus"},{"key":"ref63","article-title":"Novel treatment using low-dose naltrexone for lichen planopilaris","volume":"16","author":"Strazzulla LC","year":"2017","unstructured":"Strazzulla LC, Avila L, Lo Sicco K, Shapiro J. Novel treatment using low-dose naltrexone for lichen planopilaris. J Drugs Dermatol. 2017, 16:1140-2.","journal-title":"J Drugs Dermatol"},{"key":"ref64","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpain.2023.02.243","article-title":"The efficacy of low-dose naltrexone in pediatric chronic pain: a retrospective analysis","volume":"24","author":"Theriault C","year":"2023","unstructured":"Theriault C, Oyelola O, Zempsky WT. The efficacy of low-dose naltrexone in pediatric chronic pain: a retrospective analysis. J Pain. 2023, 24:84-85.","journal-title":"J Pain"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-243773","article-title":"Prurigo excori\u00e9e treated with low dose naltrexone","volume":"14","author":"Timoney L","year":"2021","unstructured":"Timoney L, Bunker CB. Prurigo excori\u00e9e treated with low dose naltrexone. BMJ Case Rep. 2021, 14:10.1136\/bcr-2021-243773","journal-title":"BMJ Case Rep"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.55336","article-title":"Low-dose naltrexone for excoriation disorder","volume":"16","author":"Varghese K","year":"2024","unstructured":"Varghese K, Yan X, Cao F. Low-dose naltrexone for excoriation disorder. Cureus. 2024, 16:e55336. 10.7759\/cureus.55336","journal-title":"Cureus"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1002\/glia.23157","article-title":"Therapeutic value of naltrexone as a glial modulator","volume":"65","author":"Vrooman B","year":"2017","unstructured":"Vrooman B, Toljan K, Agarwal D, Qureshi H. Therapeutic value of naltrexone as a glial modulator. GLIA. 2017, 65:e440-1. 10.1002\/glia.23157","journal-title":"GLIA"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac015.172","article-title":"Efficacy of low dose naltrexone in patients with Crohn\u2019s colitis and ileitis","volume":"28","author":"Weinstock L","year":"2022","unstructured":"Weinstock L. Efficacy of low dose naltrexone in patients with Crohn\u2019s colitis and ileitis. Inflammatory Bowel Dis. 2022, 28:S106-7. 10.1093\/ibd\/izac015.172","journal-title":"Inflammatory Bowel Dis"},{"key":"ref69","article-title":"Low-dose naltrexone therapy for psoriasis","volume":"24","author":"Weinstock LB","year":"2020","unstructured":"Weinstock LB, Cottel J, Aldridge L, Egeberg A. Low-dose naltrexone therapy for psoriasis. Int J Pharm Compd. 2020, 24:94-6.","journal-title":"Int J Pharm Compd"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2009.00613.x","article-title":"Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study","volume":"10","author":"Younger J","year":"2009","unstructured":"Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009, 10:663-72. 10.1111\/j.1526-4637.2009.00613.x","journal-title":"Pain Med"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1002\/art.37734","article-title":"Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels","volume":"65","author":"Younger J","year":"2013","unstructured":"Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013, 65:529-38. 10.1002\/art.37734","journal-title":"Arthritis Rheum"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2019.109546","article-title":"Low-dose naltrexone reduces symptoms in stiff-person syndrome","volume":"137","author":"Zappaterra M","year":"2020","unstructured":"Zappaterra M, Shouse E, Levine RL. Low-dose naltrexone reduces symptoms in stiff-person syndrome. Med Hypotheses. 2020, 137:109546. 10.1016\/j.mehy.2019.109546","journal-title":"Med Hypotheses"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.8948","article-title":"Sjogren\u2019s syndrome and clinical benefits of low-dose naltrexone therapy: additional case reports","volume":"12","author":"Zashin S","year":"2020","unstructured":"Zashin S. Sjogren\u2019s syndrome and clinical benefits of low-dose naltrexone therapy: additional case reports. Cureus. 2020, 12:e8948. 10.7759\/cureus.8948","journal-title":"Cureus"},{"key":"ref74","unstructured":"Low dose naltrexone for pain in patients with HIV. (2025). Accessed. March 23, 2025: https:\/\/clinicaltrials.gov\/study\/NCT05537935."},{"key":"ref75","unstructured":"Low-dose naltrexone for post-COVID fatigue syndrome. (2025). Accessed. March 23, 2025: https:\/\/clinicaltrials.gov\/study\/NCT05430152?term=Low%20Dose%20Naltrexone&rank=10."},{"key":"ref76","unstructured":"Low-dose naltrexone for the treatment of painful diabetic neuropathy. (2025). Accessed. March 23, 2025: https:\/\/clinicaltrials.gov\/study\/NCT04678895."},{"key":"ref77","unstructured":"Low dose naltrexone to improve physical health in patients with vasculitis (LoDoNaVasc). (2025). Accessed. March 23, 2025: https:\/\/clinicaltrials.gov\/study\/NCT03482479."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/350289-therapeutic-uses-and-efficacy-of-low-dose-naltrexone-a-scoping-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T20:35:32Z","timestamp":1742848532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/350289-therapeutic-uses-and-efficacy-of-low-dose-naltrexone-a-scoping-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":77,"URL":"https:\/\/doi.org\/10.7759\/cureus.81086","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,24]]}}}